Related Experiment Video
Updated: Jul 5, 2026
08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
Anthracycline cardiotoxicity in childhood
1Division of Paediatric Oncology, Catholic University of Rome, Rome, Italy. ruggiero@rm.unicatt.it
Pediatric Hematology and Oncology
|May 20, 2008
Summary
Childhood cancer survivors face long-term cardiac damage from treatments like anthracyclines and radiotherapy. This review explores cardiotoxicity mechanisms, screening, and prevention strategies for improved quality of life.
Area of Science:
- Oncology
- Cardiology
- Pediatric Medicine
Background:
- Significant advances in childhood and adult cancer treatment have increased survival rates over the past 40 years.
- Long-term adverse effects, particularly cardiovascular disease, significantly impact the quality of life for childhood cancer survivors.
- Cardiovascular disease is a major cause of morbidity and mortality in this population.
Purpose of the Study:
- To review the mechanisms of anthracycline cardiotoxicity.
- To discuss the cardiac damage caused by radiotherapy.
- To explore the feasibility of screening and prevention strategies for cardiac damage in childhood cancer survivors.
Main Methods:
- Literature review of studies on cancer treatment, cardiotoxicity, and survivorship.
- Analysis of mechanisms of cardiac damage induced by anthracyclines and radiotherapy.
- Evaluation of current screening protocols and preventive measures.
Main Results:
- Anthracyclines primarily affect the myocardium.
- Radiotherapy can damage all cardiac components.
- Both treatments are significant contributors to long-term cardiac damage in survivors.
Conclusions:
- Childhood cancer survivors are at high risk for treatment-related cardiac damage.
- Understanding toxicity mechanisms is crucial for developing effective screening and prevention strategies.
- Proactive cardiac care is essential to mitigate long-term morbidity and mortality.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:25Cardiomyopathy I: Introduction and Classification
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...